Maravai LifeSciences Holdings 관리

관리 기준 확인 3/4

Maravai LifeSciences Holdings CEO는 Trey Martin, Jul2023 에 임명되었습니다 의 임기는 1.33 년입니다. 총 연간 보상은 $ 2.30M, 32.6% 로 구성됩니다. 32.6% 급여 및 67.4% 보너스(회사 주식 및 옵션 포함). 는 € 2.06M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 2.06M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 4 년입니다.

주요 정보

Trey Martin

최고 경영자

US$2.3m

총 보상

CEO 급여 비율	32.6%
CEO 임기	1.3yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Trey Martin 의 보수는 Maravai LifeSciences Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$131m
Dec 31 2023	US$2m	US$750k	-US$119m
Sep 30 2023	n/a	n/a	US$25m
Jun 30 2023	n/a	n/a	US$75m
Mar 31 2023	n/a	n/a	US$153m
Dec 31 2022	US$15m	US$660k	US$220m

보상 대 시장: Trey 의 총 보상 ($USD 2.30M )은 German 시장( $USD 1.66M ).

보상과 수익: Trey 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Trey Martin (49 yo)

1.3yrs

테뉴어

US$2,301,864

보상

Mr. William E. Martin, III, also known as Trey, is Director of Maravai LifeSciences Holdings, Inc. from July 31, 2024. He was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. si...

리더십 팀

이름	위치	테뉴어	보상	소유권
Carl Hull	Co-Founder & Executive Chairman	4yrs	US$5.22m	0.21% € 4.0m
William Martin	CEO & Director	1.3yrs	US$2.30m	0.11% € 2.1m
Kevin Herde	Executive VP & CFO	7.5yrs	US$2.79m	0.021% € 393.9k
Peter Leddy	Executive VP & Chief Administrative Officer	2.4yrs	US$2.83m	0.040% € 745.6k
Christine Dolan	Executive VP & GM of Cygnus Technologies	7.1yrs	US$2.26m	0.018% € 346.6k
Andrew Burch	President of Nucleic Acid Production	1.7yrs	US$2.99m	0.023% € 425.6k
Debra Hart	Senior Director of Investor Relations	no data	데이터 없음	데이터 없음
Kurt Oreshack	Executive VP	4yrs	US$701.40k	0.018% € 340.6k
Rebecca Buzzeo	Executive VP & Chief Commercial Officer	1.8yrs	데이터 없음	0.014% € 262.0k
Kate Broderick	Chief Innovation Officer	1.8yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: MAR 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Carl Hull	Co-Founder & Executive Chairman	4yrs	US$5.22m	0.21% € 4.0m
William Martin	CEO & Director	less than a year	US$2.30m	0.11% € 2.1m
John DeFord	Independent Director	1.3yrs	US$435.03k	데이터 없음
Constantine Mihas	Non-Independent Director	4yrs	US$370.48k	0.0030% € 56.9k
Sean Cunningham	Non-Independent Director	4yrs	US$367.98k	0.0030% € 56.9k
Gregory Lucier	Independent Director	4yrs	US$360.48k	0.022% € 414.4k
Susannah Gray	Independent Director	4yrs	US$395.48k	0.026% € 481.0k
Benjamin Daverman	Non-Independent Director	4yrs	US$360.48k	0.0030% € 56.9k
Luke Marker	Non-Independent Director	4yrs	US$360.48k	0.0030% € 56.9k
Murali Prahalad	Independent Director	4yrs	US$367.98k	0.015% € 277.2k
Jessica Hopfield	Independent Director	4yrs	US$387.98k	0.047% € 880.3k

4.0yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: MAR 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Maravai LifeSciences Holdings 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Maravai Lifesciences Holdings, Inc. Appoints William “Trey” Martin, Iii to Board of Directors, Effective from July 31, 2024

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. Announces Board Changes

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

Recent updates

Maravai LifeSciences Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.056 loss per share (vs US$0.05 loss in 2Q 2023)

Maravai Lifesciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024

Maravai Lifesciences Holdings, Inc. Appoints William “Trey” Martin, Iii to Board of Directors, Effective from July 31, 2024

Maravai LifeSciences Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Small Cap Comp Value Index

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.091 loss per share (vs US$0.001 loss in 1Q 2023)

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai LifeSciences Holdings, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$0.90 loss per share (vs US$1.67 profit in FY 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Investor sentiment deteriorates as stock falls 16%

Maravai LifeSciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings released: US$0.049 loss per share (vs US$0.34 profit in 3Q 2022)

Now 27% undervalued after recent price drop

Maravai LifeSciences Holdings, Inc. Provides Updated Earnings Guidance for the Full Year 2023

Maravai LifeSciences Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 15%

Maravai Lifesciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: US$0.05 loss per share (vs US$0.54 profit in 2Q 2022)

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Maravai LifeSciences Holdings, Inc. Announces Board Changes

New major risk - Share price stability

Investor sentiment improves as stock rises 25%

First quarter 2023 earnings released: US$0.001 loss per share (vs US$0.51 profit in 1Q 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$1.67 (vs US$1.59 in FY 2021)

Maravai LifeSciences Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Investor sentiment deteriorated over the past week

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$0.46 in 3Q 2021)

Investor sentiment deteriorated over the past week

Maravai Lifesciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

Maravai LifeSciences Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Investor sentiment deteriorated over the past week

Maravai LifeSciences Announces CEO Leadership Transition

Investor sentiment improved over the past week

Maravai Lifesciences Holdings, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.44 in 2Q 2021)

Maravai LifeSciences Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Maravai LifeSciences, Inc. Appoints Peter Leddy as Executive Vice President and Chief Administrative Officer

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: US$0.51 (vs US$0.24 in 1Q 2021)

Maravai LifeSciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Maravai LifeSciences Holdings, Inc. to Report Q1, 2022 Results on May 05, 2022

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 12, 2022

Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay

Investor sentiment improved over the past week

Maravai Lifesciences Holdings, Inc. Revised Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$0.47 (vs US$0.62 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Maravai LifeSciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $1 billion.

Maravai LifeSciences Holdings, Inc. Provides Financial Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$0.44 (vs US$0.021 loss in 2Q 2020)

Investor sentiment improved over the past week

Co-Founder, President & Executive VP of Corporate Development Eric Tardif has left the company

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index